Opportunities center on rising retinal disease burden, long-acting anti-VEGF drugs, sustained-release delivery, gene and cell therapies, precision diagnostics, earlier screening, and expanded access to advanced ophthalmic care in underserved regions.
Back of the Eye Disorders Market
Dublin, Sept. 03, 2026 (GLOBE NEWSWIRE) — The “Back of the Eye Disorders Market (2nd Edition) by Scale of Operation, Type of Molecule, Target Indication, Geographical Regions, Key Players, and Sales Forecast of Commercialized Drugs – Trends and Forecast Till 2035” has been added to ResearchAndMarkets.com’s offering.
The global back of the eye disorders market is projected to grow from USD 18.28 billion in 2026 to USD 41.56 billion by 2035, representing a compound annual growth rate of 9.6% during the forecast period. Market expansion is being supported by the increasing prevalence of retinal diseases, a growing geriatric population, rising diabetes incidence, and continued innovation in ophthalmic therapeutics and ocular drug delivery technologies.
Market Growth and Emerging Treatment Trends
Therapies for posterior segment disorders address serious retinal conditions such as age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, geographic atrophy, glaucoma, and uveitic macular edema. The treatment landscape increasingly incorporates advanced biologics, next-generation anti-VEGF therapies, bispecific antibodies, sustained-release formulations, port delivery systems, and gene and cell therapies.
These innovations are intended to improve treatment durability, preserve retinal function, and reduce the frequency of intravitreal injections. Demand is also being reinforced by advances in high-resolution optical coherence tomography, wider retinal screening programs, and improved disease awareness, which support earlier diagnosis and intervention.
Nearly 200 million people worldwide are currently affected by age-related macular degeneration, and this population is expected to approach 300 million by 2040. Combined with the growing global burden of diabetes, this trend is creating sustained demand for effective long-term retinal disease management.
Key Back of the Eye Disorders Market Insights
- The development pipeline includes approximately 690 approved or clinical-stage therapeutic candidates.
- Close to 45% of posterior segment therapies are in preclinical development, with gene and cell therapies accounting for more than 30% of these candidates.
- Approximately half of gene and cell therapy candidates are administered through the intravitreal route.
- Biologics currently account for the largest market share due to their ability to target disease-associated biological pathways.
- Commercial-stage therapies represent approximately 95% of current market revenue.
- The clinical-stage segment is expected to record the fastest growth as innovative candidates progress through late-stage development.
Promising Phase III candidates include KSI-501 from Kodiak Sciences, OVX-001 from Ocuvex Therapeutics, ADX-2191 from Aldeyra Therapeutics, ONS-5010 from Outlook Therapeutics, and OTX-TKI from Ocular Therapeutix. Successful development and regulatory approval of these candidates could broaden available treatment options and support future market growth.
Diabetic Macular Edema Leads by Target Indication
Diabetic macular edema accounts for nearly 40% of the global back of the eye disorders market in 2026, making it the largest therapeutic segment. Its leadership is supported by the rising prevalence of diabetes and continued demand for established therapies, including Eylea, Eylea HD, Lumitin, Lucentis, and Vabysmo. OCS-01, an investigational therapy from Oculis, may further expand the treatment landscape following successful Phase III development and regulatory review.
Uveitic macular edema is projected to register the highest growth rate during the forecast period. Key contributing factors include unmet clinical needs, increasing adoption of long-acting intravitreal implants and targeted biologics, and improving reimbursement conditions.
Regional Market Outlook
North America is expected to maintain its leadership and account for approximately 60% of the global market by 2035. The region benefits from advanced research and manufacturing capabilities, strong academic and industry collaboration, active intellectual property development, and continued mergers and acquisitions. Bausch + Lomb’s acquisition of Whitecap Biosciences illustrates the strategic emphasis on strengthening pipelines for glaucoma and geographic atrophy therapies.
Asia-Pacific is forecast to expand at a CAGR of 11.9%, driven by increasing healthcare expenditure, improving access to advanced ophthalmic treatments, growing retinal disease awareness, and an expanding patient population. Regional pharmaceutical companies, including Astellas Pharma and Otsuka Pharmaceutical, are contributing to the development of innovative posterior segment therapies.
Market Challenges
Growth may be constrained by physiological barriers that limit drug penetration, dependence on invasive administration methods, treatment fatigue, and risks associated with repeated intravitreal injections. The chronic nature of retinal disorders also creates substantial clinical and economic burdens for patients and healthcare providers.
Additional challenges include the high cost of biologics, gene therapies, and sustained-release platforms; reimbursement limitations; variable treatment response; restricted access to specialist retinal care; lengthy clinical development timelines; stringent regulatory requirements; and complex manufacturing processes. Addressing affordability, accessibility, and treatment adherence will be critical to realizing the market’s full potential.
Competitive Landscape
Prominent companies operating in the back of the eye disorders market include AbbVie, Astellas Pharma, Bausch + Lomb, Chiesi, Genentech, Novartis, Otsuka Pharmaceutical, Regeneron Pharmaceuticals, Roche, and Sun Pharma. Competition is expected to intensify as developers pursue longer-acting therapies, differentiated mechanisms of action, and advanced delivery platforms.
Report Scope
The market report evaluates opportunities by scale of operation, molecule type, target indication, and geography. It includes analysis of clinical- and commercial-scale products; biologics and small molecules; and major indications such as diabetic macular edema, wet age-related macular degeneration, diabetic retinopathy, glaucoma, geographic atrophy, uveal melanoma, retinal vein occlusion, choroidal neovascularization, and inherited retinal disorders.
Geographic coverage includes North America, Europe, Asia-Pacific, the Middle East and North Africa, and Latin America. The research also examines market drivers, restraints, opportunities, competitive positioning, company portfolios, development pipelines, routes of administration, dosing frequency, mechanisms of action, regulatory designations, and recent industry developments.
The report provides revenue forecasts, segment-level opportunity analysis, company profiles, market competitiveness assessments, and strategic insights designed to support pharmaceutical companies, biotechnology developers, investors, healthcare organizations, and new market entrants in informed decision-making.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 278 |
| Forecast Period | 2026-2035 |
| Estimated Market Value (USD) in 2026 | $18.28 Billion |
| Forecasted Market Value (USD) by 2035 | $41.56 Billion |
| Compound Annual Growth Rate | 9.6% |
| Regions Covered | Global |
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Molecular Therapeutics
- AAVantgarde
- AAVINUE
- AbbVie
- Abeona Therapeutics
- Abpro
- ActiveSite Pharmaceuticals
- ADARx Pharmaceuticals
- Adverum Biotechnologies (Subsidiary of Eli Lilly)
- Afecta Pharmaceuticals
- AffaMed Therapeutics
- AiViva Biopharma
- Alder Therapeutics
- Aldeyra Therapeutics
- Alkeus Pharmaceuticals
- Allegro Ophthalmics (Acquired by Bausch + Lomb)
- Allgenesis Biotherapeutics
- Amarna Therapeutics
- Amyndas Pharmaceuticals
- ANBITION
- Angios FlexCo
- Annexin Pharmaceuticals
- Annexon Biosciences
- Apellis Pharmaceuticals
- Applied Therapeutics
- AptaBio
- Arctic Vision
- Argo Biopharma
- Ascidian Therapeutics
- AsclepiX Therapeutics
- Ashvattha Therapeutics
- Astellas Pharma
- Atsena Therapeutics
- Augelux Therapeutics (Previously known as Zhongmou Therapeutics)
- Aura Biosciences
- Aviceda Therapeutics
- Avirmax
- Avista Therapeutics
- Bausch + Lomb
- BDgene
- Beacon Therapeutics
- Beijing StarMab Biomed Technology
- Belite Bio
- BenoBio
- Betaliq
- BioCryst Pharmaceuticals
- Bionic Sight
- Biophytis
- Bio-Thera Solutions
- Biovista
- BlueRock Therapeutics
- Boehringer Ingelheim
- Breye Therapeutics
- BSIM Therapeutics
- Ceregene (Acquired by Sangamo Therapeutics)
- Celliaz
- Character Biosciences
- Chengdu Kanghong Pharmaceutical
- Chiesi Group
- CiRC Biosciences
- Cirrus Therapeutics
- Clearside Biomedical
- Cloudbreak Pharma
- Coave Therapeutics
- Complement Therapeutics
- CS Pharmaceuticals
- Curacle
- Daewoong Pharmaceutical
- Diorasis Therapeutics
- Dompe
- Drive Therapeutics
- Eclipse Life Sciences
- EIR Biopharma
- Elgan Pharma
- Elisigen
- Eluminex Biosciences
- Emaris Bio
- EmendoBio
- Emmecell
- Endogena Therapeutics
- Epicrispr Biotechnologies
- Everads Therapy
- Everglades Biopharma
- Evergreen Therapeutics
- Excitant Therapeutics
- Exonate
- EyeGene
- EyePoint Pharmaceuticals
- Eyestem Research
- FELIQS
- FireCyte Therapeutics
- ForwardVue Pharma
- Frontera Therapeutics
- Galimedix Therapeutics
- GelMEDIX
- Genentech (A subsidiary of Roche)
- GenSight Biologics
- Glaukos
- Glycadia
- Gyre Therapeutics
- Healios K.K
- Huabo Biopharm
- HuidaGene Therapeutics
- Hyperion Therapeutics (Acquired by Amgen)
- IDEAYA Biosciences
- Ikarovec
- Immunocore
- Inflammasome Therapeutics
- InflammX Therapeutics
- INGENIA Therapeutics
- InMed Pharmaceuticals
- InnoVec Biotherapeutics
- Innovent Biologics
- insitro
- Iolyx Therapeutics
- iOnctura
- Isarna Therapeutics
- iVIEW Therapeutics
- jCyte
- Jingze Biotech
- Johnson & Johnson
- JW Holdings
- KALA BIO
- KalVista Pharmaceuticals
- Kanaph Therapeutics
- Kiora Pharmaceuticals
- Kodiak Sciences
- Kriya Therapeutics
- Kubota Vision
- Kuria Therapeutics
- Kyoto Drug Discovery & Development
- Kyowa Kirin
- Lan-yi Therapeutics
- Limnopharma
- Lineage Cell Therapeutics
- Mabwell
- Mediphage
- MeiraGTx
- Merck
- MimeTech
- Miramoon Pharma
- Mireca Medicines
- MitoChem Therapeutics
- Mogrify
- Nacuity Pharmaceuticals
- Naegis Pharmaceuticals
- Nanoscope Therapeutics
- NatureCeuticals
- NEORTESBIO
- NeuMedics
- Neurophth Therapeutics
- Neurotech Pharmaceuticals
- Neuvasq Biotechnologies
- Nicox
- Novaliq
- Novartis
- Novelty Nobility
- Noveome Biotherapeutics
- Oak Hill Bio
- Octant
- Ocugen
- Ocular Therapeutix
- Oculis
- Oculogenex
- OcuMension Therapeutics
- OcuTerra Therapeutics
- Ocutheia
- Ocuvex Therapeutics
- Odylia Therapeutics
- OliPass
- OliX Pharmaceuticals
- Ollin Biosciences
- OMEICOS Therapeutics
- ONL Therapeutics
- Ophthalmic Therapeutic Innovation
- OphtiMedRx
- Opthea
- Optigo Biotherapeutics
- Opus Genetics
- Otsuka Pharmaceutical
- Outlook Therapeutics
- Palatin Technologies
- Pangea Bio
- Peptitech
- Perceive Biotherapeutics
- PharmAbcine
- Pinotbio
- PLABiologics
- PulseSight Therapeutics
- PYC Therapeutics
- Qlaris Bio
- Ray Therapeutics
- ReBio Pharma
- Regeneron Pharmaceuticals
- Relin Medicine
- Replimune
- Restore Vision
- RetinalGeniX
- Retinset
- Retrotope
- Re-Vana Therapeutics
- reVision Therapeutics
- RevOpsis Therapeutics
- Rezolute
- RIBOMIC
- Ripple Therapeutics
- Roca Therapeutics
- Roche
- Rophibio
- Rznomics
- SanBio
- Sanofi
- Santen Pharmaceutical
- SCAI Therapeutics
- SciNeuro Pharmaceuticals
- SeaBeLife
- Seinda
- SemaThera
- Senju Pharmaceutical
- Shanghai Henlius Biotech
- Shanghai SIMR Biotechnology
- Shenzhen Oculgen Biomedical Technology
- Singh Biotechnology
- SiNOPSEE Therapeutics
- SmartinBio
- SparingVision
- SpliceBio
- Stealth BioTherapeutics
- Stoke Therapeutics
- Stuart Therapeutics
- Sumitomo Pharma
- Sun Pharma
- SunRegen Healthcare
- Sunshine Guojian Pharmaceutical
- Surrozen
- Sylentis
- Tarsier Pharma
- Tavo Biotherapeutics
- TeamedOn
- TelomEYE
- Telomir Pharmaceuticals
- Tenpoint Therapeutics
- Theialife
- TheratOcular Biotek
- Therini Bio
- UgeneX Therapeutics
- Uni-Bio Science
- Valitor
- Vantage Biosciences
- VCCT
- VeonGen Therapeutics
- Verseon
- VIAN Therapeutics
- Vitreo Pharma
- Vzarii Therapeutics
- YD Life Science
For more information about this report visit https://www.researchandmarkets.com/r/19yo5k
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Back of the Eye Disorders Market
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
